Advertisement

Tumor Biology

, Volume 34, Issue 1, pp 81–90 | Cite as

Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy

  • Oliver J. Stoetzer
  • Debora M. I. Fersching
  • Christoph Salat
  • Oliver Steinkohl
  • Christian J Gabka
  • Ulrich Hamann
  • Michael Braun
  • Axel-Mario Feller
  • Volker Heinemann
  • Barbara Siegele
  • Dorothea Nagel
  • Stefan HoldenriederEmail author
Research Article

Abstract

Neoadjuvant chemotherapy in breast cancer patients aims at preoperative reduction of tumor volume for better resection results and prognosis. As not all patients respond to neoadjuvant therapy, predictive biomarkers are needed for more efficient individual management. In prospectively collected sera of 51 consecutive locally confined breast cancer (LBC) patients receiving preoperative, neoadjuvant chemotherapy, value level kinetics of soluble high mobility group box 1 (HMGB1), soluble receptor for advanced glycation end products (sRAGE) as well as the established breast cancer biomarkers CA 15–3 and carcinoembryonic antigen (CEA) were investigated and correlated with therapy response objectified by pathological staging at surgery. In addition, biomarkers were measured in sera of 30 healthy controls (HC), 13 patients with benign breast diseases, and 28 metastatic breast cancer (MBC) patients. Pretherapeutic levels of soluble HMGB1 were decreased in MBC, while sRAGE was already decreased in LBC. In contrast, CA 15–3 and CEA were strongly elevated in MBC, but not in LBC. Combination of sRAGE and CA 15–3 enabled best discrimination of LBC from HC (AUC 78.2 %; sens 58 % at 95 % spec), while CA15-3 and CEA discriminated best between MBC and all controls (AUC 90.9 %; sens 70 % at 95 % spec). In LBC patients undergoing neoadjuvant chemotherapy, nine patients achieved complete remission (CR), 29 achieved partial remission (PR), while 13 had no change of disease (NC). NC patients tended to have higher HMGB1 and lower sRAGE levels before therapy onset (p = 0.056 and p = 0.054), while CA 15–3 and CEA did not predict therapeutic outcome. Furthermore, kinetics of HMGB1 during therapy correlated with efficacy of the treatment (p = 0.053). Markers of immunogenic cell death are valuable for the diagnosis of MBC and early estimation of response to neoadjuvant therapy in LBC patients.

Keywords

Breast cancer Chemotherapy Therapy monitoring Immunogenic cell death Biomarkers HMGB1 RAGE CA 15–3 CEA Serum 

Supplementary material

13277_2012_513_MOESM1_ESM.ppt (504 kb)
ESM 1 (PPT 503 kb)

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Ozols RF, Herbst RS, Colson YL, et al. American Society of Clinical Oncology. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol. 2007;25:146–62.PubMedCrossRefGoogle Scholar
  3. 3.
    Bundret NJ. Prognostic and predictive factors in breast cancer. Cancer Trial Rev. 2001;27:137–42.CrossRefGoogle Scholar
  4. 4.
    Von Minckwitz G. Neoadjuvant chemotherapy in breast cancer—insights from the German experience. Breast Cancer 2012; published online.Google Scholar
  5. 5.
    EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group. Lancet. 2005;365:1687–717.CrossRefGoogle Scholar
  6. 6.
    Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102.PubMedCrossRefGoogle Scholar
  7. 7.
    Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–85.PubMedCrossRefGoogle Scholar
  8. 8.
    Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19:1508–16.PubMedCrossRefGoogle Scholar
  9. 9.
    Beachy SH, Repasky EA. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol Immunother. 2008;57:759–75.PubMedCrossRefGoogle Scholar
  10. 10.
    Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54:e11–79.PubMedCrossRefGoogle Scholar
  11. 11.
    Holdenrieder S, Stieber P. Apoptotic markers in cancer. Clin Biochem. 2004;37:605–17.PubMedCrossRefGoogle Scholar
  12. 12.
    Holdenrieder S, Stieber P. Clinical use of circulating nucleosomes. Crit Rev Lab Med Sci. 2009;46:1–24.CrossRefGoogle Scholar
  13. 13.
    Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367–88.PubMedCrossRefGoogle Scholar
  14. 14.
    Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59–73.PubMedCrossRefGoogle Scholar
  15. 15.
    Holdenrieder S, Stieber P, von Pawel J, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non small cell lung cancer. Clin Cancer Res. 2004;10:5981–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Holdenrieder S, Stieber P, von Pawel J, et al. Early and specific prediction of the therapeutic efficacy in lung cancer by nucleosomal DNA and cytokeratin 19 fragments. Ann N Y Acad Sci. 2006;1075:244–75.PubMedCrossRefGoogle Scholar
  17. 17.
    Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Bianchi ME. HMGB1 loves company. J Leukocyte Biology. 2009;86:573–76.CrossRefGoogle Scholar
  19. 19.
    Urbonaviciute V, Fürnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G, Rovere-Querini P, Herrmann M, Voll RE. Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med. 2008;205:3007–18.PubMedCrossRefGoogle Scholar
  20. 20.
    Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death and Differentiation. 2008;15:3–12.PubMedCrossRefGoogle Scholar
  21. 21.
    Park JS. G-RF, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, et al.: High mobility group box 1 protein interacts with multiple toll-like receptors. Am J Physiol Cell Physiol. 2006;290:917–24.CrossRefGoogle Scholar
  22. 22.
    Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, Kroemer G. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis. 2009;14:364–75.PubMedCrossRefGoogle Scholar
  23. 23.
    Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 2008;68:4026–30.PubMedCrossRefGoogle Scholar
  25. 25.
    Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D, Lim JB. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med. 2009;7:38.PubMedCrossRefGoogle Scholar
  26. 26.
    Naumnik W, Nilklińska W, Ossolińska M, Chyczewska E. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Folia Histochem Cytobiol. 2009;47:703–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Tang DL, Kang R, Zeh HJ, Lotze MT. High-mobility group box 1 and cancer. Biochimica Et Biophysica Acta-Gene Regulatory Mechanisms. 2010;1799:131–40.CrossRefGoogle Scholar
  28. 28.
    Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologica. 2009;52:2251–63.CrossRefGoogle Scholar
  29. 29.
    Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ, Lotze MT. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. Journal of Translational Medicine. 2010;7:17.CrossRefGoogle Scholar
  30. 30.
    Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem. 2006;13:1971–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRefGoogle Scholar
  32. 32.
    Lehner J, Wittwer C, Fersching D, Siegele B, Holdenrieder S, Stoetzer OJ. Methodical and preanalytical evaluation of an HMGB1 immunoassay. Anticancer Res. 2012;32:2059–62.PubMedGoogle Scholar
  33. 33.
    Wittwer C, Lehner J, Fersching D, Siegele B, Stoetzer OJ, Holdenrieder S. Methodical and preanalytical evaluation of a RAGE immunoassay. Anticancer Res. 2012;32:2075–78.PubMedGoogle Scholar
  34. 34.
    Holdenrieder S, Nagel D, Stieber P. Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer. Cancer Biomarkers. 2010;6:179–90.PubMedGoogle Scholar
  35. 35.
    Barak V, Holdenrieder S, Nisman B, Stieber P. Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. Cancer Biomarkers. 2010;6:191–6.PubMedGoogle Scholar
  36. 36.
    Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2010;11:36–44.PubMedCrossRefGoogle Scholar
  37. 37.
    Holdenrieder S. v Pawel J, Dankelmann E, et al. Nucleosomes, ProGRP, NSE, CYFRA 21–1 and CEA in the therapy monitoring of small-cell lung cancer during first-line chemotherapy. Clin Cancer Res. 2008;14:7813–21.PubMedCrossRefGoogle Scholar
  38. 38.
    Kremer A, Wilkowski R, Holdenrieder S, et al. Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumour Biol. 2005;26:44–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Kremer A, Holdenrieder S, Stieber P, et al. Nucleosomes in colorectal cancer patients during radiochemotherapy. Tumour Biol. 2006;27:235–42.PubMedCrossRefGoogle Scholar
  40. 40.
    Stötzer OJ, Fersching DIM, Salat C, Siegele B, Nagel D, Holdenrieder S. Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating circulating nucleosomes, DNAse activity, M30 and survivin. Cancer Lett, submittedGoogle Scholar
  41. 41.
    Jiao L, Weinstein SJ, Albanes D, Taylor PR, Graubard BI, Virtamo J, Stolzenberg-Solomon RZ. Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study. Cancer Res. 2011;71:3582–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Krechler T, Jáchymová M, Mestek O, Zák A, Zima T, Kalousová M. Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer. Clin Biochem. 2010;43:882–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Jiao L, Taylor PR, Weinstein SJ, Graubard BI, Virtamo J, Albanes D, Stolzenberg-Solomon RZ. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:1430–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Jing R, Cui M, Wang J, Wang H. Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma. 2010;57:55–61.PubMedCrossRefGoogle Scholar
  45. 45.
    Tesarová P, Kalousová M, Jáchymová M, Mestek O, Petruzelka L, Zima T. Receptor for advanced glycation end products (RAGE)—soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest. 2007;25:720–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Shang GH, Jia CQ, Tian H, Xiao W, Li Y, Wang AH, Dong L, Lin DJ. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med. 2009;103:1949–53.PubMedCrossRefGoogle Scholar
  47. 47.
    Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, Zhang ZL, Fan W, Li YQ. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis. 2008;40:446–52.PubMedCrossRefGoogle Scholar
  48. 48.
    Sheng X, Du X, Zhang X, Li D, Lu C, Li Q, Ma Z, Song Q, Wang C. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croat Med J. 2009;50:455–64.PubMedCrossRefGoogle Scholar
  49. 49.
    Urbonaviciute V, Fürnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, Voll RE. Factors masking HMGB1 in human serum and plasma. J Leukoc Biol. 2007;81:67–74.PubMedCrossRefGoogle Scholar
  50. 50.
    Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P. Tumor markers in breast cancer—European Group on Tumor Markers recommendations. Tumour Biol. 2005;26:281–93.PubMedCrossRefGoogle Scholar
  51. 51.
    Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, Stieber P. Importance of CEA and CA 15–3 during disease progression in metastatic breast cancer patients. Anticancer Res. 2007;27:1963–8.PubMedGoogle Scholar
  52. 52.
    Molina R, Gion M, Gressner A, Troalen F, Auge JM, Holdenrieder S, Zancan M, Wycislo M, Stieber P. Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access BR Monitor assay on the UniCel Dxl 800 Immunoassay System. Clin Chem Lab Med. 2008;46:612–22.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Oliver J. Stoetzer
    • 1
  • Debora M. I. Fersching
    • 2
  • Christoph Salat
    • 1
  • Oliver Steinkohl
    • 3
  • Christian J Gabka
    • 3
  • Ulrich Hamann
    • 4
  • Michael Braun
    • 4
  • Axel-Mario Feller
    • 5
  • Volker Heinemann
    • 6
  • Barbara Siegele
    • 2
  • Dorothea Nagel
    • 2
  • Stefan Holdenrieder
    • 2
    • 7
    Email author
  1. 1.Haematology and Oncology Outpatient Cancer Care CenterMunichGermany
  2. 2.Institute of Clinical ChemistryUniversity Hospital MunichMunichGermany
  3. 3.Breast Cancer Center Klinikum Dritter OrdenMunichGermany
  4. 4.Red Cross Breast Cancer Center IIMunichGermany
  5. 5.Breast Cancer Center Dr. GeisenhoferMunichGermany
  6. 6.Medical Clinic IIIUniversity Hospital MunichMunichGermany
  7. 7.Institute of Clinical Chemistry and Clinical PharmacologyUniversity Hospital BonnBonnGermany

Personalised recommendations